Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
September 09, 2024 07:00 ET
|
Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...
Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections
January 16, 2024 06:00 ET
|
Intravacc B.V.
Intravacc secures $633K funding from CARB-X to develop a vaccine against or Neisseria gonorrhoeae.
Gonorrhea Therapeutics Market Surpass USD 2 billion in Revenues by 2027 Says, Transparency Market Research
September 26, 2023 10:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - According to TMR, gonorrhea therapeutics are expected to expand at a 5.3% CAGR from 2019...
Gonorrhea Pipeline Analysis: Emerging Therapies and Key Companies Transforming the Gonorrhea Landscape
March 24, 2021 21:10 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, March 24, 2021 (GLOBE NEWSWIRE) -- Gonorrhea Pipeline Analysis: Emerging Therapies and Key Companies Transforming the Gonorrhea Landscape Gonorrhea Pipeline report provides...
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
September 30, 2019 01:00 ET
|
Entasis Therapeutics Holdings Inc.
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections...
Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
July 17, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford,...
Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
June 20, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Oxford, UK, and Cambridge, MA, US,...
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
March 14, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at...
Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
February 25, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant...
SpeeDx Receives CE-IVD Mark for ResistancePlus® GC Gonorrhea Test
December 06, 2018 03:30 ET
|
SpeeDx Pty Ltd
SYDNEY, Australia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted...